Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,145 JPY | -2.90% | -3.29% | -14.10% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company is not the most generous with respect to shareholders' compensation.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.10% | 5.71B | C+ | ||
-39.33% | 13.67B | B- | ||
-8.96% | 7.95B | B | ||
+4.90% | 5.86B | C | ||
-3.07% | 4.55B | D- | ||
+70.58% | 4.5B | C | ||
-8.29% | 3.77B | B | ||
-22.05% | 3.05B | C- | ||
-13.61% | 2.81B | C- | ||
-11.32% | 2.57B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3088 Stock
- Ratings MatsukiyoCocokara & Co.